Clinical Trials Browser

Recurrence × Thoracic × 30 days × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Recurrence, Stomach Neoplasms

NCT07509034 2026-04-17

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Phase 1 Not yet recruiting

40 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT03460977 2026-04-16

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

453 enrolled

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

56 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT07277413 2026-04-03

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Phase 1 Recruiting

260 enrolled

GastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT05815160 2026-03-30

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Active not recruiting

34 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT05669846 2026-03-23

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Phase 2 Recruiting

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT05283330 2026-03-20

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Phase 1 Recruiting

48 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Glioblastoma, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT05537740 2026-03-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

129 enrolled

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

Clinical Trials

JIVAN

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors